Nmpa
Entity.
- Evidence
- 22 documents · 12 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 3 Sept 2026, last seen 7 Oct 2026
- Measured
- 18% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- AllSci News · 2026-10-07 · ArriVent's firmonertinib falls short in global Phase III EGFR exon 20 trial (opens the source in a new tab)
- Billboard Business · 2026-10-05 · The Next Battle Over Songwriter Streaming Royalties Has Begun. Don’t Expect a Quick Fight (opens the source in a new tab)
- PR Newswire · 2026-10-02 · Úbytek hmotnosti o 19,3 % ve 48. týdnu: Na EASD byla představena studie fáze III zaměřené na regulaci tělesné hmotnosti s olatorepatidem od Hansoh (opens the source in a new tab)
- AllSci News · 2026-10-02 · Phrontline brings FRα×CDH6 dual-payload ADC into the clinic in China, US (opens the source in a new tab)
- CNBC · 2026-10-02 · Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion (opens the source in a new tab)
- Memeburn · 2026-09-30 · The Honor Watch 6 Pro Doesn’t Measure Your Blood Sugar, and Its Cardiac Arrest Alert Isn’t the First of Its Kind (opens the source in a new tab)
- newindianexpress · 2026-09-30 · Massive explosion at MRPL refinery in Mangaluru triggers panic; rescue operations underway (opens the source in a new tab)
- Clinical Trials Arena · 2026-09-28 · Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC (opens the source in a new tab)
- The Clinical Trial Vanguard · 2026-09-28 · Innovent Expands Phase 3 MarsLight-11 Trial of IBI363/TAK-928 to Non-Squamous NSCLC (opens the source in a new tab)
- Clinical Trials Arena · 2026-09-28 · Akeso begins Phase III study of cadonilimab for gastric cancer (opens the source in a new tab)
- Billboard Business · 2026-09-25 · Phono V Could Reshape Catalog Valuations for Years. Here’s Why Songwriters Should Pay Attention (Guest Column) (opens the source in a new tab)
- Clinical Trials Arena · 2026-09-20 · China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours (opens the source in a new tab)